Cargando…

Classification of Muscle Invasive Bladder Cancer to Predict Prognosis of Patients Treated with Immunotherapy

BACKGROUND: Recently, immunotherapies have been approved for advanced muscle invasive bladder cancer (MIBC) treatment, but only a small fraction of MIBC patients could achieve a durable drug response. Our study is aimed at identifying tumor microenvironment (TME) subtypes that have different immunot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhifeng, Li, Xiqing, Wang, Xiaoqing, Liu, Jie, Wang, Lingdian, Wei, Wei, Duan, Xiaoyu, Ding, Degang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170513/ https://www.ncbi.nlm.nih.gov/pubmed/35677536 http://dx.doi.org/10.1155/2022/6737241

Ejemplares similares

Chronic kidney disease and functional impairment in a longitudinal study of older adults in China
por: Duan, Xiaoyu, et al.
Publicado: (2023)

Efficacy and safety of intra-arterial chemotherapy combined with intravesical chemotherapy for high-risk non-muscle invasive bladder cancer: A protocol for a systematic review and meta-analysis
por: Li, Xing, et al.
Publicado: (2019)

Segmental ureterectomy for high-risk ureteral carcinoma: a preliminary report
por: Wei, Wei, et al.
Publicado: (2023)

Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer
por: Zhang, Qi, et al.
Publicado: (2022)

The 1973 WHO Classification Is More Suitable than the 2004 WHO Classification for Predicting Prognosis in Non-Muscle-Invasive Bladder Cancer
por: Chen, Zhongqing, et al.
Publicado: (2012)

Perioperative immunotherapy for muscle-invasive bladder cancer
por: Kim, In-Ho, et al.
Publicado: (2020)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
por: Peyrottes, Arthur, et al.
Publicado: (2021)

Perioperative immunotherapy in muscle-invasive bladder cancer
por: Lee, Hyung Ho, et al.
Publicado: (2020)

Identification of prognostic and immunotherapy-related eRNA ID2-AS1 in bladder cancer
por: Zhang, Lei, et al.
Publicado: (2022)

Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling
por: Zhou, Xianghong, et al.
Publicado: (2020)

Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma
por: Zong, Yuan, et al.
Publicado: (2023)

A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer
por: Wang, Weizhuo, et al.
Publicado: (2023)

ISPRF: a machine learning model to predict the immune subtype of kidney cancer samples by four genes
por: Wang, Zhifeng, et al.
Publicado: (2021)

A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer
por: Zheng, Xiaonan, et al.
Publicado: (2021)

An innovative risk index based on neutrophils and macrophages can effectively predict prognosis and immunotherapy response in patients with muscle-invasive bladder cancer
por: Zhang, Xingxing, et al.
Publicado: (2023)

Multiomics analysis of ferroptosis-related molecular subtypes in muscle-invasive bladder cancer immunotherapy
por: Wang, Haojie, et al.
Publicado: (2022)

A single-sample mRNA molecular classification of bladder cancer predicting prognosis and response to immunotherapy
por: Jin, Kun, et al.
Publicado: (2022)

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
por: Kamoun, Aurélie, et al.
Publicado: (2019)

Thulium Laser Resection of Bladder Tumors vs. Conventional Transurethral Resection of Bladder Tumors for Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer Followed by Intravesical BCG Immunotherapy
por: Liu, Zheng, et al.
Publicado: (2021)

Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer
por: Jiang, Xiumei, et al.
Publicado: (2016)

Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer
por: Zhou, Lin, et al.
Publicado: (2021)

Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification
por: Yuk, Hyeong Dong, et al.
Publicado: (2019)

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
por: Renner, Alex, et al.
Publicado: (2021)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer
por: Ying, Yidie, et al.
Publicado: (2023)

Multi‐omics consensus ensemble refines the classification of muscle‐invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapies
por: Lu, Xiaofan, et al.
Publicado: (2021)

Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature
por: Liu, Hua-Ping, et al.
Publicado: (2023)

New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis
por: Pane, Katia, et al.
Publicado: (2020)

Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer
por: Zhu, Huier, et al.
Publicado: (2019)

Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer
por: Wang, Yejinpeng, et al.
Publicado: (2020)

Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022)

Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non‐muscle‐invasive bladder cancer
por: Ye, Kun, et al.
Publicado: (2022)

Identification and Verification of Immune Subtype-Related lncRNAs in Clear Cell Renal Cell Carcinoma
por: Wang, Zhifeng, et al.
Publicado: (2022)

Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer
por: Xu, Yan, et al.
Publicado: (2023)

Smoking Behaviors and Prognosis in Patients With Non–Muscle-Invasive Bladder Cancer in the Be-Well Study
por: Kwan, Marilyn L., et al.
Publicado: (2022)

Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer
por: Suh, Jungyo, et al.
Publicado: (2020)

Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2023)

Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer
por: Zhong, Wenlong, et al.
Publicado: (2020)

Controlling Nutritional Status Score Evaluates Prognosis in Patients With Non-Muscle Invasive Bladder Cancer
por: Huang, Jiaguo, et al.
Publicado: (2021)

PTEN-related risk classification models for predicting prognosis and immunotherapy response of hepatocellular carcinoma
por: Cao, Lu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8oqaj0jjra5lsufo491k6aqis4